121 related articles for article (PubMed ID: 2120175)
1. Ceftibuten--in-vitro activity against respiratory pathogens, beta-lactamase stability and mechanism of action.
Wise R; Andrews JM; Ashby JP; Thornber D
J Antimicrob Chemother; 1990 Aug; 26(2):209-13. PubMed ID: 2120175
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
Jones RN; Biedenbach DJ; Croco MA; Barrett MS
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):573-8. PubMed ID: 9764398
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarhallis.
Doern GV
Diagn Microbiol Infect Dis; 1991; 14(1):75-7. PubMed ID: 1901536
[TBL] [Abstract][Full Text] [Related]
4. In-vitro antimicrobial activity of 7432-S (SCH39720) against commonly isolated respiratory tract pathogens.
Jones RN; Barry AL
J Antimicrob Chemother; 1988 Sep; 22(3):387-9. PubMed ID: 3141348
[No Abstract] [Full Text] [Related]
5. [Serotype distribution and drug resistance of
Tian HL; Shi W; Zhou HF; Yuan L; Yao KH; Rexiati D; Xu AM
Zhonghua Er Ke Za Zhi; 2018 Apr; 56(4):279-283. PubMed ID: 29614568
[No Abstract] [Full Text] [Related]
6. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests with Haemophilus influenzae.
Doern GV; Vautour R
Diagn Microbiol Infect Dis; 1992; 15(7):633-40. PubMed ID: 1424521
[TBL] [Abstract][Full Text] [Related]
8. Postantibiotic effect of ceftibuten on respiratory pathogens.
Chin NX; Huang HB; Neu HC
Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S84-7. PubMed ID: 7567315
[TBL] [Abstract][Full Text] [Related]
9. Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom.
Wise R; Andrews JM; Ashby JP; Thornber D
Diagn Microbiol Infect Dis; 1991; 14(1):45-52. PubMed ID: 2013210
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and beta-lactamase producing bacteria.
Cormican MG; Jones RN
J Antimicrob Chemother; 1995 Apr; 35(4):535-9. PubMed ID: 7628987
[TBL] [Abstract][Full Text] [Related]
11. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
Blondeau JM; Suter M; Borsos S
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.
Blandino G; Aleo G; Caccamo F; Nicolosi VM; Siracusa V; Speciale A
J Chemother; 1996 Jun; 8(3):193-9. PubMed ID: 8808715
[TBL] [Abstract][Full Text] [Related]
13. Killing rate and growth rate comparison for newer beta-lactamase-stable oral beta-lactams against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
Yourassowsky E; Van der Linden MP; Crokaert F
Chemotherapy; 1992; 38(1):7-13. PubMed ID: 1618006
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.
Elshafie SS; Al-Kuwari J
Int J Antimicrob Agents; 2004 Sep; 24(3):309-10. PubMed ID: 15325441
[No Abstract] [Full Text] [Related]
15. Activity of oral beta-lactam antimicrobial agents versus respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the era of antibiotic resistance.
Doern GV
Otolaryngol Head Neck Surg; 2002 Dec; 127(6 Suppl):S17-23. PubMed ID: 12511856
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of a new broad-spectrum, beta-lactamase-stable oral cephalosporin, cefixime, in comparison with other drugs, against Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis and Streptococcus pneumoniae.
Stefani S; Pellegrino MB; D'Amico G; Privitera A; Privitera O; Maccarrone G; Russo G; Nicoletti G
Chemotherapy; 1992; 38(1):36-45. PubMed ID: 1618002
[TBL] [Abstract][Full Text] [Related]
17. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Pfaller MA; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
[TBL] [Abstract][Full Text] [Related]
18. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.
Hoban DJ; Doern GV; Fluit AC; Roussel-Delvallez M; Jones RN
Clin Infect Dis; 2001 May; 32 Suppl 2():S81-93. PubMed ID: 11320449
[TBL] [Abstract][Full Text] [Related]
19. [Antibiotic resistance: an always present problem].
Debbia EA
Recenti Prog Med; 1999 Oct; 90(10):505-9. PubMed ID: 10592734
[No Abstract] [Full Text] [Related]
20. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan.
Lau YJ; Hsueh PR; Liu YC; Shyr JM; Huang WK; Teng LJ; Liu CY; Luh KT
Microb Drug Resist; 2006; 12(2):130-5. PubMed ID: 16922631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
